Europe Pharmaceutical Drug Delivery market

The Europe pharmaceutical drug delivery market is projected to reach USD 703.2 million by 2031 from USD 519.6 million in 2026 at  a CAGR of  6.2% during the forecast period.

The Europe pharmaceutical drug delivery market is growing in response to the increasing use of biologics and biosimilars, the rising prevalence of chronic diseases, and the growing acceptance of emerging drug delivery devices, including auto-injectors, prefilled syringes, and inhalation drug delivery devices. Furthermore, an aging population, growing usage of home care, and supportive regulatory policies that encourage patient-friendly drug delivery systems are also driving this market. The major trends in this market are self-administration, technology-driven drug delivery, sustainable drug delivery, and drug device combinations.

To know about the assumptions considered for the study download the pdf brochure

Some of the prominent players operating in the Europe market include Johnson & Johnson Services, Inc. (US), Pfizer Inc. (US), Fresenius Kabi (Germany), Becton, Dickinson and Company (US), Nemera (France), B. Braun (Germany), Gerresheimer AG (Germany), SHL Medical (Switzerland), Novo Nordisk (Denmark), Novartis (Switzerland), Sanofi (France), Baxter International (US), AstraZeneca (UK), Roche (Switzerland), and medmix (Switzerland).

• In May 2024, Novartis took a step to expand its cancer care portfolio through the acquisition of Mariana Oncology, which, in turn, provides the company with access to next-generation radioligand therapies for the most challenging oncology issues.
• In July 2023, GSK expanded its respiratory pipeline through the acquisition of Bellus Health, which introduced camlipixant, a late-stage P2X3 antagonist for refractory chronic cough.
• In June 2023, Merck expanded into the immunology and gastroenterology fields via the acquisition of Prometheus, which brought to the company innovative products for the treatment of ulcerative colitis, Crohn’s disease, and other autoimmune issues.
• In June 2023, Merck expanded its immunology and gastroenterology pipeline via the acquisition of Prometheus, which brought into the company innovative candidates for ulcerative colitis, Crohn’s disease, and other autoimmune conditions.

Fresenius Kabi (Germany)

Fresenius Kabi, a German company, has a company profile that classifies it as a world leader in pharmaceuticals for injectables, infusion therapies, nutrient-related care, and drug delivery devices. This analysis regards Fresenius Kabi as a major player in the pharmaceutical drug delivery industry. Fresenius Kabi has a wide distribution of subsidiaries in many nations. These subsidiaries include Fresenius Kabi USA in the USA, Calea GmbH in Germany, and Fresenius Kabi Austria GmbH in Austria. Other markets for Fresenius Kabi are Germany, France, the UK, Spain, Italy, and China.

Johnson & Johnson Services,  Inc. (US)

Johnson & Johnson, through its pharmaceutical arm Janssen, is one of the largest and most influential players in the Europe pharmaceutical drug delivery market due to its extensive portfolio of advanced therapies, strong R&D capabilities, and continuous investment in innovative delivery systems. The company has established leadership in long-acting injectables, controlled-release formulations, targeted drug delivery platforms, and self-administration devices, supporting the growing demand for biologics, oncology treatments, and immunotherapies. J&J’s deep expertise in material science, device engineering, and formulation technology enables the development of highly stable, patient-friendly delivery mechanisms, including depot injections, transdermal systems, and smart connected devices that improve adherence and therapeutic outcomes. With significant manufacturing capac ity, strategic collaborations, and a consistent focus on innovation in drug-device combination products, Johnson & Johnson plays a pivotal role in shaping advancements in drug delivery across the US pharmaceutical landscape.

Pfizer Inc. (US)

Pfizer Inc. is a significant and highly influential player in the Europe pharmaceutical drug delivery market, supported by its expansive portfolio of innovative therapeutics, leadership in mRNA technology, and continuous advancement of drug-device combination products. The company’s pioneering work in nucleic acid–based delivery platforms, including lipid nanoparticle (LNP) systems used in mRNA vaccines and emerging gene-therapy candidates, has positioned Pfizer at the forefront of next-generation drug delivery innovation. Pfizer also develops a wide range of oral, injectable, inhalation, and sustained-release formulations tailored to enhance bioavailability, therapeutic precision, and patient adherence across various therapeutic areas, including immunology, oncology, cardiovascular disease, and infectious disorders. Its strong collaboration ecosystem, deep formulation expertise, and significant US manufacturing footprint enable rapid scale-up and reliable supply of advanced delivery systems. Moreover, Pfizer’s continued investments in digital health integration, self-administration technologies, and improved delivery mechanisms for complex biologics further reinforce its position as one of the most dominant and progressive players in the Europe pharmaceutical drug delivery market.

Market Ranking

In the European market, firms such as Johnson & Johnson, Pfizer, Fresenius Kabi, BD, and Novartis are driving the pharmaceutical drug delivery market with their distinct approaches. These consist of wide-ranging portfolios in biologics and injectables, robust hospital distribution networks, and a continuous emphasis on innovation in drug delivery, including automated injectors, prefilled syringes, and infusion devices. Their focus on patient-driven self-administration, heavy investment in products, and wide manufacturing and distribution networks in major European markets further support their competitiveness.

Related Reports:

Europe Pharmaceutical Drug Delivery Market By Route of Administration [Oral (Tablet, Capsule), Injector, Topical (Cream, Transdermal Patch), Transmucosal, Nasal], Application [Cancer, Diabetes], Care Setting [Hospital, Homecare]-Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com